Plcoskin
Seoul
About Plcoskin
Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare. They have developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper. Plcoskin’s scaffolds are made with synthetic PCL, a biodegradable material that is commonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin’s PCL scaffolds are absorbed and replaced with the recipient’s own natural tissues, minimizing the possibility of long-term side effects. As they do not contain any dangerous chemicals, they are also 50% safer than cadaver-sourced scaffolds. Costs for reconstructive breast surgery are brought down by 40% to only $3 thousand per breast. Furthermore, much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. The mesh design of the scaffolds mitigates the need for an additional follow-up reconstructive surgery, something that is common when using cadaver-sourced scaffolds. Plcoskin has also developed Youlief, a cosmeceutical product & therapeutic device pipeline that helps fund R&D for their medical devices. Youlief is available in the US, Europe, Taiwan, Singapore and Japan.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $5.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2023)
- Website: plcoskin.com
- Phone: +82 2-3446-0601
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/plcoskin-74482 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.